We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+0.54%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.46B
AUM Growth
-$483M
(-16%)
Cap. Flow
-$259M
Cap. Flow
% of AUM
-10.54%
Top 10 Holdings %
Top 10 Hldgs %
47.28%
Holding
112
New
8
Increased
8
Reduced
35
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Erasca
ERAS
|
+$217M |
| 2 |
Immuneering
IMRX
|
+$60.5M |
| 3 |
Tango Therapeutics
TNGX
|
+$37.1M |
| 4 |
Cytokinetics
CYTK
|
+$29.4M |
| 5 |
Tyra Biosciences
TYRA
|
+$20.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Atea Pharmaceuticals
AVIR
|
+$41.1M |
| 2 |
Twist Bioscience
TWST
|
+$24.7M |
| 3 |
XLRN
Acceleron Pharma
XLRN
|
+$22M |
| 4 |
908 Devices
MASS
|
+$21.1M |
| 5 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$13.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.61% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWTX
101
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-15,000
| Closed | -$1.24M |
|
102
Theravance Biopharma
TBPH
$877M
| – | – |
-300,000
| Closed | -$4.36M |
|
|
103
Twist Bioscience
TWST
$7.25B
| – | – |
-185,000
| Closed | -$24.7M |
|
104
Zai Lab
ZLAB
$2.62B
| – | – |
-53,455
| Closed | -$9.46M |
|
|
EIGR
105
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| – | – |
-9,500
| Closed | -$2.43M |
|
|
GTH
106
DELISTED
Genetron Holdings Limited ADS
GTH
| – | – |
-44,289
| Closed | -$2.68M |
|
|
HGEN
107
DELISTED
HUMANIGEN, INC.
HGEN
| – | – |
-600,000
| Closed | -$10.4M |
|
|
TCDA
108
DELISTED
Tricida, Inc. Common Stock
TCDA
| – | – |
-427,975
| Closed | -$1.85M |
|
|
FVAM
109
DELISTED
5:01 Acquisition Corp
FVAM
| – | – |
-400,000
| Closed | -$3.99M |
|
|
XLRN
110
DELISTED
Acceleron Pharma
XLRN
| – | – |
-175,000
| Closed | -$22M |
|
|
CEREW
111
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
| – | – |
-19,316
| Closed | -$278K |
|
|
AVEO
112
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| – | – |
-893,500
| Closed | -$5.89M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
C
TCM
BGM
Cormorant Asset Management's Q3 2021 Portfolio in Review
As of Q3 2021, Cormorant Asset Management held 112 positions worth $2.46B, down 16% from $2.94B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Cormorant Asset Management withdrew a net $259M in Q3 2021, closing 24 positions and reducing 35 holdings. Its most notable exit was Twist Bioscience, an estimated $24.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 86% a quarter earlier, followed by Financials.
Against the trend, Cormorant Asset Management opened a new position in Erasca worth $217M.
- Cormorant Asset Management's largest Q3 2021 buy was Erasca: 10,505,550 shares worth $217M.
- Cormorant Asset Management added most to Tango Therapeutics in Q3 2021, an estimated $37.1M increase.
- Cormorant Asset Management's biggest Q3 2021 reduction was Atea Pharmaceuticals, cutting an estimated $41.1M.
- Cormorant Asset Management fully exited Twist Bioscience in Q3 2021, selling an estimated $24.7M.
- Cormorant Asset Management's ten largest holdings make up 47% of its $2.46B portfolio in Q3 2021.
- Cormorant Asset Management opened 8 new positions and closed 24 in Q3 2021.
- Cormorant Asset Management's portfolio value fell 16% quarter-over-quarter to $2.46B.
Based on Cormorant Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.